NovoPro
Cart 2
  • Anti-EGFR/HER1/ErbB1 antibody

Anti-EGFR/HER1/ErbB1 antibody

Cat.#: 103190

Special Price 145.0 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    Anti-EGFR/HER1/ErbB1 antibody
  • Documents
  • Description
    Mouse monoclonal to EGFR/HER1/ErbB1
  • Tested applications
    ELISA
  • Species reactivity
    Human EGFR / ErbB / HER1
    No cross-reactivity in ELISA with Human EGFR/ErbB1; Human ErbB2; Human ErbB3; Human ErbB4; Human cell lysate (293 cell line)
  • Immunogen
  • Isotype
    Mouse IgG2b
  • Preparation
    This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human EGFR / ErbB / HER1 (rh EGFR / ErbB / HER1; Met 1-Ser 645; NP_005219). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
  • Clonality
    Monoclonal
  • Formulation
    0.2 μm filtered solution in PBS with 5% trehalose
  • Storage instructions
    This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
    Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
  • Applications

    ELISA: 0.5-1 μg/mL

    This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Human EGFR. The detection limit for Human EGFR is approximately 0.0195 ng/well.

  • Validations
  • Background
    As a member of the epidermal growth factor receptor (EGFR) family, EGFR protein is type I transmembrane glycoprotein that binds a subset of EGF family ligands including EGF, amphiregulin, TGF-α, betacellulin, etc. EGFR protein plays a crucial role in signaling pathway in the regulation of cell proliferation, survival and differentiation. Binding of a ligand induces EGFR protein homo- or heterodimerization, the subsequent tyrosine autophosphorylation and initiates various down stream pathways (MAPK, PI3K/PKB and STAT). In addition, EGFR signaling also has been shown to exert action on carcinogenesis and disease progression, and thus EGFR protein is proposed as a target for cancer therapy currently.
  • References
    • Schlessinger, J. (2000) Cell signaling by receptor tyrosine kinases. Cell 103(2): 211-25.
    • Giaccone, G. (2005) HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann. Oncol. 16(4): 538-48.
    • Yarden, Y., et al. (2001) Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2(2): 127-37.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"